Slide 1: Welcome to the 2021 Financial Report webcast
1 Welcome to the 2021 Financial Report webcast NNIT A/S January 28 1
Slide 2: Representing NNIT A/S today
Representing NNIT A/S today Pär Fors Pernille Fabricius Chief Executive Officer Chief Financial Officer 2
Slide 3: Agenda
Agenda 01 Highlights for Q4 2021 02 Financial performance 03 Balance sheet and cash flow 04 Outlook for 2022 05 Closing remarks 3
Slide 4: Forward-looking statements
Forward-looking statements This announcement contains forward-looking statements. Words such as ‘believe’, ‘expect’, ‘may’, ‘will’, ‘plan’, ‘strategy’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘outlook’, ‘guidance’, ‘target’ and other words and terms of similar me
Slide 5: Agenda
Agenda 01 Highlights for Q4 2021 02 Financial performance 03 Balance sheet and cash flow 04 Outlook for 2022 05 Closing remarks 5
Slide 6: NNIT is on a strategic journey
NNIT is on a strategic journey NNIT is growing – We are optimistic most notably within about the future Life Sciences Solutions We’re remodeling the We are addressing our challenges now car as we’re driving it and for the future 6
Slide 7: Business Highlights Q4 2021
Business Highlights Q4 2021 Major organizational Special items of change to create three DKK 61 million distinct business units Major wins with: Nordic Regional Most attractive Security Coordinator workplace in Denmark E-nettet for IT consultants 2021 (both low triple-digit DKK million amounts) 7
Slide 8: A new three-divisional organization
A new three-divisional organization NNIT Life Sciences Cloud & Digital Hybrid Cloud Solutions Solutions Solutions 8 PUBLIC
Slide 9: Old org. vs new organization
Old org. vs new organization From To Life Sciences Life Sciences Cloud & Digital Hybrid Cloud Focus Solutions Solutions Solutions on P/L Private & Public Sales Sales Sales Business Business Business Development Development Development Cloud & Digital Delivery Delivery Delivery Infrastructure Outsour
Slide 10: ESG rating improved (down from 17.1 to 13.3)
ESG rating improved (down from 17.1 to 13.3)
Slide 11: Agenda
Agenda 01 Highlights for Q4 2021 02 Financial performance 03 Balance sheet and cash flow 04 Outlook for 2022 05 Closing remarks 11
Slide 12: Q4 2021 & FY 2021 at a glance
Q4 2021 & FY 2021 at a glance Revenue Winning solutions Operating profit* Investment level** DKK 738m DKK 406 DKK 37m DKK 20m Q4 2021 -1.5% growth 55% 5.0% 2.7% -6.7% organic growth % of revenue operating profit margin % of revenue Revenue Winning solutions Operating profit* Investment level** DKK 2
Slide 13: Group Performance Overview
Group Performance Overview Q4 2021 FY 2021 DKK million Q4 2021 Q4 2020 Change FY 2021 FY 2020 Change Revenue 738 749 -1,5% 2.877 2.830 1,7% Cost of goods sold 653 638 2,4% 2.533 2.443 3,7% Gross profit 85 111 -23,4% 344 387 -11,1% Gross profit margin 11,5% 14,8% -3,3pp 12,0% 13,7% -1.7pp Sales and m
Slide 14: Life Sciences
Life Sciences Q4 2021 FY 2021 DKK million Q4 2021 Q4 2020 Change FY 2021 FY 2020 Change Life Sciences (excl. NNG) 262 203 29,1% 970 717 35,3% Life Sciences (Int.) 200 136 47,1% 711 456 55,9% Life Sciences (DK) 62 67 -7,5% 259 261 -0,8% Novo Nordisk Group 153 209 -26,8% 605 732 -17,3% Revenue 415 412
Slide 15: Private & Public
Private & Public Q4 2021 FY 2021 DKK million Q4 2021 Q4 2020 Change FY 2021 FY 2020 Change Enterprise 190 172 10,5% 725 712 1,8% Public 68 104 -34,6% 309 407 -24,1% Finance 65 61 6,6% 268 262 2,3% Revenue 323 337 -4,2% 1.302 1.381 -5,7% Cost of goods sold 298 300 -0,7% 1.191 1.238 -3,8% Gross profit
Slide 16: Agenda
Agenda 01 Highlights for Q4 2021 02 Financial performance 03 Balance sheet and cash flow 04 Outlook for 2022 05 Closing remarks 16
Slide 17: Balance sheet
Balance sheet Assets Dec 31, Dec 31, Equity and liabilities Dec 31, Dec 31, DKK million 2021 2020 DKK million 2021 2020 Intangible assets 945 781 Share capital 250 250 Tangible assets 483 552 Treasury shares -2 -3 Lease assets 173 227 Retained earnings 863 855 Contract assets 39 75 Other reserves 31
Slide 18: Cash flows
Cash flows Cash flow Q4 2021 Q4 2020 FY 2021 FY 2020 DKK million Net profit for the period 2 18 -7 76 Reversal of non-cash items 79 -53 335 228 Interest paid -4 -5 -17 -16 Income taxes paid 17 -10 4 -42 Cash flow before change in working capital 94 -50 315 246 Changes in working capital 40 232 -72 2
Slide 19: Agenda
Agenda 01 Highlights for Q4 2021 02 Financial performance 03 Balance sheet and cash flow 04 Outlook for 2022 05 Closing remarks 19
Slide 20: Backlog development, current year
Backlog development, current year Backlog for the year, beginning of Q1 2022 +0.9% (+18) • At the beginning of Q4 2022, NNIT’s order entry backlog for 2022 3,000 2,790 2,643 amounted to DKK 2,017 million, up 0.9% from last year. 2,500 2,379 • Life Sciences (excl. NNG) customers increased by 14.2%. 9
Slide 21: Outlook
Outlook 2022 Revenue growth 2-5% Operating profit margin Around 5% before special items Special items Up to the same level as in 2021 21
Slide 22: Agenda
Agenda 01 Highlights for Q4 2021 02 Financial performance 03 Balance sheet and cash flow 04 Outlook for 2022 05 Closing remarks 22
Slide 23: Closing remarks
Closing remarks Increased guidance on Life Sciences revenue growth, Focus on the new International continued while maintaining organizational structure the strong growth in financial guidance on and leadership to enhance Q4 2021 with revenue operating profit increasing 47% compared the growth path a
Slide 24: Questions
Questions ANIT
Slide 25: Investor contact information
Investor contact information Financial Calendar Investor contact March 10, 2022 • Annual General Meeting Pernille Fabricius May 6, 2022 • Interim report for the first three months of 2022 August 12, 2022 • Interim report for the first six months of 2022 November 2, 2022 • Interim report for the firs
Slide 26: We make a mark
We make a mark nnit.com ANIT